Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

beCLomethasone Efficacy in Acute Rhinosinusitis - CLEAR Study

This study has been completed.
Information provided by (Responsible Party):
Chiesi Farmaceutici S.p.A. Identifier:
First received: August 1, 2012
Last updated: July 23, 2014
Last verified: July 2014

Intranasal corticosteroids are beneficial in the treatment of acute rhinosinusitis. As adjunctive therapy to oral antibiotic treatment, mometasone furoate at doses of 200 μg or 400 μg twice daily, was well tolerated and significantly more effective in reducing the symptoms of rhinosinusitis than antibiotic therapy alone. Furthermore,the addition of fluticasone propionate to xylometazoline and antimicrobial therapy with cefuroxime improved clinical success rates and accelerated recovery of patients with a history of chronic rhinitis or recurrent sinusitis who present for treatment of acute rhinosinusitis.

The present study was planned to assess the effects of nebulised beclomethasone dipropionate given as add-on therapy to standard care (oral antibiotics) in the treatment of acute symptomatic rhinosinusitis. Antibiotic therapy will be at the physicians' discretion.

Condition Intervention Phase
Acute Rhinosinusitis
Drug: beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days
Drug: placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Multicentre, Randomized, Double-blind, Parallel Group, Placebo-Controlled Study on the Therapeutic Efficacy and Safety of Beclomethasone Dipropionate Suspension for Inhalation 800 µg Twice Daily vs. Placebo Added to Antibiotic Therapy in Patients With Acute Rhinosinusitis

Resource links provided by NLM:

Further study details as provided by Chiesi Farmaceutici S.p.A.:

Primary Outcome Measures:
  • proportion of patients who will experience clinical success [ Time Frame: 28 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • overall sinus symptoms [ Time Frame: 7,14,21,28 days ] [ Designated as safety issue: No ]
  • changes of each symptom [ Time Frame: 7, 14, 21, 28 days ] [ Designated as safety issue: No ]
  • level of work performance based on patient perception (recorded on a VAS scale of the diary card) and on missed working time [ Time Frame: 7, 14 days ] [ Designated as safety issue: No ]
  • absence of relapses [ Time Frame: 7, 14, 21, 28 days ] [ Designated as safety issue: No ]
  • nasal mucociliary transport time [ Time Frame: 7, 14 days ] [ Designated as safety issue: No ]
  • nasal air flow resistance [ Time Frame: 7, 14 days ] [ Designated as safety issue: No ]
  • Adverse events and adverse drug reactions [ Time Frame: 0, 7, 14, 21, 28 days ] [ Designated as safety issue: Yes ]
  • vital signs [ Time Frame: 0, 7, 14, 21, 28 days ] [ Designated as safety issue: Yes ]

Enrollment: 166
Study Start Date: January 2013
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: beclomethasone dipropionate
beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days
Drug: beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days
Placebo Comparator: placebo
placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days
Drug: placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject's written informed consent obtained prior to any study-related procedures
  2. Male and female out-patients aged between 18 and 65 years (inclusive).
  3. History of previously diagnosed recurrent or chronic sinusitis that necessitate antibiotic therapy as judged by the investigator.
  4. Clinical diagnosis of acute rhinosinusitis defined, according to the European Position Paper on Rhinosinusitis and Nasal Polyps 2007 (20), as the sudden onset of two or more relevant symptoms for <12 weeks, at least one of which is:

    • Nasal blockage/obstruction/congestion, OR
    • Nasal discharge (anterior/posterior nasal drip);

    AND the second one is:

    • Facial pain/pressure or/and reduction/loss of sense of smell.

  5. A cooperative attitude and ability to be trained to use correctly the nebuliser with intranasal nose piece.

Exclusion Criteria:

  1. Previous sinus surgery;
  2. Sinus lavage within the past 7 days;
  3. Nasal polyposis or important nasal septum deviation;
  4. Antibiotic use (by any route) in the past 30 days;
  5. Recurrent moderate epistaxis;
  6. Chronic bacterial sinusitis with evidence of failure of antimicrobial therapy;
  7. Intranasal or systemic use of corticosteroids within the past 30 days;
  8. Chronic use of corticosteroids or immunosuppressive agents;
  9. Immunocompromised states;
  10. Diagnosis of bronchial asthma or chronic obstructive pulmonary disease (COPD);
  11. History of clinically significant cardiac (i.e. congestive heart failure or severe hypertension), renal (i.e. kidney failure), psychiatric (i.e. depression or mood disorders), hepatic (i.e. cholestatic jaundice or hepatic dysfunction), endocrine (i.e. hyperthyroidism or adrenal suppression) or pulmonary disease, or laboratory testing abnormalities, whose sequelae and/or treatments can interfere with the results or treatments of the present study;
  12. History of psychiatric diseases likely to require treatment with antidepressant drugs during the study period or treatment with antidepressant drugs in the past 2 weeks;
  13. Diagnosis of glaucoma or prostatic hypertrophy;
  14. History of alcohol or drug abuse;
  15. Allergy, sensitivity or intolerance to study drugs and/or study drugs formulations ingredients (e.g. corticosteroids);
  16. Pregnant or lactating women or all women physiologically capable of becoming pregnant UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/mL or are using one or more of the following acceptable methods of contraception. surgical sterilization (e.g. bilateral tubal ligation, hysterectomy) hormonal contraception (implantable, patch, oral) double-barrier methods (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap). A pregnancy test (urine) will be performed at screening in women of childbearing potential.
  17. Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study.
  18. Participation in another trial in the past 12 weeks or patients previously enrolled in this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01691677

Ospedale Cisanello
Pisa, Italy
Policlinico Univesitario Gemelli
Roma, Italy
Policlinico Santa Maria alle Scotte
Siena, Italy
Sponsors and Collaborators
Chiesi Farmaceutici S.p.A.
  More Information

No publications provided

Responsible Party: Chiesi Farmaceutici S.p.A. Identifier: NCT01691677     History of Changes
Other Study ID Numbers: MC/PR/1400/007/11
Study First Received: August 1, 2012
Last Updated: July 23, 2014
Health Authority: Italy: Ethics Committee

Additional relevant MeSH terms:
Nose Diseases
Otorhinolaryngologic Diseases
Paranasal Sinus Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Anti-Asthmatic Agents
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses processed this record on November 20, 2014